Antiretroviral Drug Resistance in a Respondent-Driven Sample of HIV-Infected Men Who Have Sex With Men in Brazil

Carregando...
Imagem de Miniatura
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
BERMUDEZ-AZA, Elkin Hernan
KERR, Ligia Regina Franco Sansigolo
KENDALL, Carl
PINHO, Adriana Araujo
MELLO, Maeve Brito de
MOTA, Rosa Salani
GUIMARAES, Mark Drew Crosland
BRITO, Ana Maria de
DOURADO, Ines Costa
Citação
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, v.57, suppl.3, p.S186-S192, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: There are few studies on HIV subtypes and primary and secondary antiretroviral drug resistance (ADR) in community-recruited samples in Brazil. We analyzed HIV clade diversity and prevalence of mutations associated with ADR in men who have sex with men in all five regions of Brazil. Methods: Using respondent-driven sampling, we recruited 3515 men who have sex with men in nine cities: 299 (9.5%) were HIV-positive; 143 subjects had adequate genotyping and epidemiologic data. Forty-four (30.8%) subjects were antiretroviral therapy-experienced (AE) and 99 (69.2%) antiretroviral therapy-naive (AN). We sequenced the reverse transcriptase and protease regions of the virus and analyzed them for drug resistant mutations using World Health Organization guidelines. Results: The most common subtypes were B (81.8%), C (7.7%), and recombinant forms (6.9%). The overall prevalence of primary ADR resistance was 21.4% (i.e. among the AN) and secondary ADR was 35.8% (i.e. among the AE). The prevalence of resistance to protease inhibitors was 3.9% (AN) and 4.4% (AE); to nucleoside reverse transcriptase inhibitors 15.0% (AN) and 31.0% (AE) and to nonnucleoside reverse transcriptase inhibitors 5.5% (AN) and 13.2% (AE). The most common resistance mutation for nucleoside reverse transcriptase inhibitors was 184V (17 cases) and for nonnucleoside reverse transcriptase inhibitors 103N (16 cases). Conclusions: Our data suggest a high level of both primary and secondary ADR in men who have sex with men in Brazil. Additional studies are needed to identify the correlates and causes of antiretroviral therapy resistance to limit the development of resistance among those in care and the transmission of resistant strains in the wider epidemic.
Palavras-chave
HIV-1, men who have sex with men, respondent-driven sampling, Brazil, antiretroviral resistance
Referências
  1. Ferreira JLD, 2008, MEM I OSWALDO CRUZ, V103, P800, DOI 10.1590/S0074-02762008000800010
  2. Kendall C, 2008, AIDS BEHAV, V12, pS97, DOI 10.1007/s10461-008-9390-4
  3. Perez L, 2007, AIDS RES HUM RETROV, V23, P407, DOI 10.1089/aid.2006.0155
  4. Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/01.aids.0000060345.12269.d7
  5. Sprinz E, 2009, AIDS RES HUM RETROV, V25, P861, DOI 10.1089/aid.2009.0012
  6. Santos AF, 2007, JAIDS-J ACQ IMM DEF, V45, P328
  7. Magnani R, 2005, AIDS, V19, pS67, DOI 10.1097/01.aids.0000172879.20628.e1
  8. Rodrigues R, 2006, VIRUS RES, V116, P201, DOI 10.1016/j.virusres.2005.10.004
  9. Booth CL, 2007, J ANTIMICROB CHEMOTH, V59, P1047, DOI 10.1093/jac/dkm082
  10. Baral S, 2007, PLOS MED, V4, P1901, DOI 10.1371/journal.pmed.0040339
  11. Goel S, 2010, P NATL ACAD SCI USA, V107, P6743, DOI 10.1073/pnas.1000261107
  12. Sucupira MCA, 2007, AIDS PATIENT CARE ST, V21, P116, DOI 10.1089/apc.2006.0079
  13. Yerly S, 2009, AIDS, V23, P1415, DOI 10.1097/QAD.0b013e32832d40ad
  14. Jakobsen MR, 2010, CLIN INFECT DIS, V50, P566, DOI 10.1086/650001
  15. Gorbach PM, 2008, JAIDS-J ACQ IMM DEF, V47, P639, DOI 10.1097/QAI.0b013e3181684c3d
  16. Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
  17. Vercauteren J, 2009, J INFECT DIS, V200, P1503, DOI 10.1086/644505
  18. Araujo LV, 2006, GENET MOL RES, V5, P203
  19. Bennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724
  20. Brigido LFM, 2007, AIDS RES HUM RETROV, V23, P1579, DOI 10.1089/aid.2007.0102
  21. Deeks SG, 2009, CLIN INFECT DIS, V49, P1582, DOI 10.1086/644768
  22. DiazGranados CA, 2010, INT J INFECT DIS, V14, pE298, DOI 10.1016/j.ijid.2009.05.006
  23. Dumans AT, 2004, J INFECT DIS, V189, P1232, DOI 10.1086/382483
  24. Hance AJ, 2001, J VIROL, V75, P6410, DOI 10.1128/JVI.75.14.6410-6417.2001
  25. Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
  26. Kijak GH, 2001, ANTIVIR THER, V6, P71
  27. Machado ES, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004806
  28. Moreno S, 2010, J ANTIMICROB CHEMOTH, V65, P827, DOI 10.1093/jac/dkq061
  29. Nunn AS, 2007, PLOS MED, V4, P1804, DOI 10.1371/journal.pmed.0040305
  30. Pedroso C, 2007, JAIDS-J ACQ IMM DEF, V45, P251, DOI 10.1097/QAI.0b013e318050d8b0
  31. Sa Filho Dercy José de, 2005, AIDS Res Hum Retroviruses, V21, P145
  32. Soares MA, 2004, AIDS, V18, pS9, DOI 10.1097/01.aids.0000131317.90644.c9
  33. Walter H, 2002, JAIDS, V31, P137, DOI 10.1097/01.QAI.0000032640.13616.AC